Table of Contents
Overview
New York, NY – April 28, 2025 – Global Cancer Biopsy Market size is expected to be worth around USD 75.1 Billion by 2033 from USD 26.2 Billion in 2023, growing at a CAGR of 11.1% during the forecast period from 2024 to 2033.
A cancer biopsy is a critical medical procedure used to diagnose the presence of cancer by removing and examining tissue or cell samples from the body. It remains the gold standard for confirming cancer, providing detailed insights into the type, stage, and aggressiveness of the disease. Biopsies help doctors develop personalized treatment plans, improving patient outcomes significantly.
There are several types of biopsy techniques, including needle biopsy, surgical biopsy, endoscopic biopsy, and image-guided biopsy. The selection of the method depends on the tumor’s location, size, and suspected cancer type. Advanced technologies, such as liquid biopsies, are also emerging, offering minimally invasive alternatives by analyzing cancer cells or DNA from blood samples.
The global need for accurate and early cancer diagnosis continues to grow. According to the World Health Organization (WHO), cancer accounted for nearly 10 million deaths worldwide in 2020. Early detection through biopsy procedures is crucial for increasing survival rates and reducing the burden of cancer. Continuous advancements in biopsy technologies and molecular diagnostic tools are enhancing the accuracy, speed, and safety of cancer detection. The critical role of biopsies underscores their importance in modern oncology, ensuring better diagnosis, targeted therapies, and improved patient care.
Key Takeaways
- Market Size: The global cancer biopsy market is projected to reach approximately USD 75.1 billion by 2033, rising from USD 26.2 billion in 2023.
- Market Growth: The market is anticipated to expand at a robust Compound Annual Growth Rate (CAGR) of 11.1% during the forecast period from 2024 to 2033.
- Product Analysis: Based on product segmentation, the market is categorized into instruments, kits & consumables, and services. The kits & consumables segment dominated in 2023, accounting for 63% of the total revenue share.
- Type Analysis: In terms of type, the market is segmented into tissue biopsy, liquid biopsy, and others. Tissue biopsy led the segment in 2023, capturing 64% of the overall market share.
- Application Analysis: By application, the market encompasses breast cancer, colorectal cancer, lung cancer, prostate cancer, blood cancer, skin cancer, kidney cancer, liver cancer, pancreatic cancer, and others. Breast cancer held the highest share among applications, contributing 18% to the market in 2023.
- Regional Analysis: North America emerged as the leading region in the cancer biopsy market, securing the largest revenue share of 42% in 2023.
- Technological Advancements: The introduction of advanced techniques such as liquid biopsy and next-generation sequencing is significantly accelerating market growth.
- Early Diagnosis Focus: The rising emphasis on early detection of cancer is increasing the demand for accurate and minimally invasive biopsy procedures.
- Government Support: Favorable government initiatives and increased funding for cancer research are playing a crucial role in boosting market expansion.
Segmentation Analysis
- By Type Analysis: In 2023, the tissue biopsy segment led the market, securing a 64% share due to its status as the primary method for cancer diagnosis. Tissue biopsies are regarded as essential by healthcare professionals for determining cancer type, tumor behavior, resistance mutations, and gene expression profiles. Continuous advancements in tissue biopsy technologies further strengthen its position. This segment is expected to witness substantial growth over the coming years, supported by the irreplaceable clinical importance of tissue biopsy procedures.
- By Application Analysis: Breast cancer held an 18% share of the cancer biopsy market in 2023, reflecting its high prevalence. Risk factors include smoking, alcohol consumption, dense breast tissues, genetic mutations (BRCA1, BRCA2, CHEK2), and aging. Data from breastcancer.org suggests that approximately 13% of women in the United States—equivalent to one in eight women—will develop invasive breast cancer during their lifetime. The rising incidence rate underscores the critical need for reliable and early biopsy-based diagnosis in breast cancer care.
- By Product Analysis: In 2023, the kits and consumables segment dominated the product category, capturing a 63% revenue share. These products are essential across all biopsy stages, from sample collection to analysis. Major industry players have heavily invested in advancing kits and consumables through dedicated research and development activities. The global rise in cancer cases has further intensified demand for efficient, high-precision consumables, solidifying their crucial role in ensuring accuracy and enhancing the overall efficacy of biopsy procedures.
Market Segments
By Product
- Instruments
- Kits & Consumables
- Services
By Type
- Tissue Biopsy
- Needle Biopsy
- Surgical Biopsy
- Liquid Biopsy
- Others
By Application
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Prostate Cancer
- Blood Cancer
- Skin Cancer
- Kidney Cancer
- Liver Cancer
- Pancreatic Cancer
- Others
Regional Analysis
North America Leads the Cancer Biopsy Market
In 2024, North America held the dominant position in the cancer biopsy market, accounting for more than 42% of the total revenue. This leadership is attributed to the region’s advanced healthcare infrastructure and the high prevalence of cancer. Manufacturers in North America are focusing on developing novel diagnostic kits designed for rapid and accurate cancer detection. Additionally, the growing adoption of liquid biopsies in the United States is supported by favorable government initiatives. Notably, the U.S. Food and Drug Administration (FDA) has established regulatory frameworks to facilitate the development of liquid biopsy-based oncology diagnostics.
Asia Pacific Poised for the Highest Growth Rate
The Asia Pacific region is projected to witness the highest compound annual growth rate (CAGR) during the forecast period. This growth can be attributed to the increasing population, rising healthcare expenditures, and continuous advancements in biopsy technologies. Emerging economies such as China and India are investing heavily in healthcare infrastructure, enabling broader access to cancer diagnostic procedures. Furthermore, intensified research and development efforts in advanced cancer diagnostics are expected to drive market expansion across the region in the coming years.
Emerging Trends
Liquid Biopsy: A Less Invasive Diagnostic Tool
Liquid biopsy is a technique that detects cancer-related materials, such as circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), in body fluids like blood. This method allows for real-time monitoring of tumor dynamics and can reflect the genetic makeup of both primary and metastatic lesions. It offers a less invasive alternative to traditional tissue biopsies and facilitates sequential monitoring of disease progression and treatment response .
Statistical Biopsy: Leveraging Personal Health Data
Statistical biopsy is an emerging approach that utilizes personal health data, including clinical, demographic, and lifestyle information, to predict cancer risk. By applying deep learning models to large datasets, such as the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial and the UK Biobank, researchers can assess an individual’s risk for various cancers, enabling personalized early detection strategies.
AI-Powered Histopathological Analysis:
Artificial intelligence (AI) is increasingly being used to analyze histopathological images of tumor biopsies. For instance, researchers at Stanford have developed an AI tool that predicts the activity of thousands of genes within tumor cells based on standard microscopy images. This approach can expedite clinical decision-making and reduce the need for costly genomic tests.
Use Cases
Early Detection of Cancer: Biopsies are critical for the early detection of cancer. For example, a new blood test developed in the U.S. has demonstrated the ability to identify 18 early-stage cancers by analyzing blood proteins. In a study involving 440 individuals already diagnosed with cancer, the test correctly identified 93% of stage 1 cancers in men and 84% in women.
Treatment Planning and Monitoring: Biopsy results guide treatment decisions by providing information on tumor type, grade, and molecular characteristics. For instance, assessing PD-L1 expression through small biopsy samples can inform the use of immunotherapies in non-small cell lung cancer patients.
Minimally Invasive Diagnostic Options: Needle biopsies, such as fine-needle aspiration and core needle biopsy, offer less invasive diagnostic options compared to surgical biopsies. In breast cancer diagnosis, the use of needle biopsy as the initial procedure has been associated with a reduced likelihood of multiple surgeries.
Conclusion
Cancer biopsy continues to be a cornerstone in the accurate diagnosis and personalized treatment of cancer. Advancements such as liquid biopsy, AI-driven histopathology, and statistical biopsy techniques are enhancing early detection, improving patient outcomes, and reducing procedural invasiveness.
Rising global cancer incidence, government initiatives, and technological innovations are further driving market growth. North America leads the market, while Asia Pacific is projected to experience the fastest growth. As precision medicine advances, the role of biopsy in oncology will become even more critical, ensuring better-targeted therapies, faster diagnosis, and more effective management of cancer worldwide.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
